The Health Outcomes Liaison (HOL) team serves as the medical and health economic and outcomes research (HEOR) interface between Lilly and U.S. population-based decision makers (PBDMs) including payers, health systems, research institutions, and policy makers. The HOL role provides answers to customer questions with clinical evidence, HEOR, and real-world evidence (RWE) to support formulary access and pathways/guidelines decisions impacting millions of patients. The HOL is acutely attuned to therapeutic evidence gaps, understands environmental trends, and anticipates stakeholder evidence needs. The HOL role is a key component of meeting customer needs and improving patient outcomes for Lilly.